CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
tumors are confirmed by surgery and pathologyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03009318
NCT03009318N/ACompleted

Combination of 11C-MET PET and MRS in the Diagnosis of Glioma.

Huashan Hospital·interventional·Posted Jan 4, 2017·Updated Apr 9, 2018

In Brief

A clinical study evaluating tumors are confirmed by surgery and pathology for Glioma. Completed, enrolled 100 participants across 1 site.

Detailed Summary

MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2017
Enrollment StartJan 1, 2012
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.5 years ago

Interventions

tumors are confirmed by surgery and pathologyother

Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.